- Previous Close
163.13 - Open
163.59 - Bid 164.48 x 800
- Ask 164.49 x 900
- Day's Range
162.91 - 164.52 - 52 Week Range
140.68 - 169.99 - Volume
3,055,203 - Avg. Volume
9,057,381 - Market Cap (intraday)
394.944B - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
28.31 - EPS (TTM)
5.79 - Earnings Date Apr 15, 2025
- Forward Dividend & Yield 4.96 (3.04%)
- Ex-Dividend Date Feb 18, 2025
- 1y Target Est
169.07
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.
www.jnj.com138,100
Full Time Employees
December 29
Fiscal Year Ends
Sector
Industry
Recent News: JNJ
View MorePerformance Overview: JNJ
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: JNJ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: JNJ
View MoreValuation Measures
Market Cap
393.12B
Enterprise Value
405.23B
Trailing P/E
28.17
Forward P/E
15.41
PEG Ratio (5yr expected)
1.11
Price/Sales (ttm)
4.46
Price/Book (mrq)
5.50
Enterprise Value/Revenue
4.56
Enterprise Value/EBITDA
16.35
Financial Highlights
Profitability and Income Statement
Profit Margin
15.84%
Return on Assets (ttm)
8.13%
Return on Equity (ttm)
20.06%
Revenue (ttm)
88.82B
Net Income Avi to Common (ttm)
14.07B
Diluted EPS (ttm)
5.79
Balance Sheet and Cash Flow
Total Cash (mrq)
24.52B
Total Debt/Equity (mrq)
52.92%
Levered Free Cash Flow (ttm)
16.67B